Virica Biotech and FUJIFILM Biosciences Collaborate Under the Canada–Japan Co‑Innovation Program to Advance AAV Production Enhancers
8.4.2026 15:00:00 CEST | Business Wire | Press Release
Virica Biotech (“Virica”), a cell enhancer company specializing in Viral Sensitizers (VSE™) for viral vector manufacturing, today announced it is receiving advisory services and funding from the National Research Council of Canada Industrial Research Assistance Program (NRC IRAP), under the Canada–Japan Corporate Co-Innovation Program for a collaboration with FUJIFILM Biosciences. The collaboration will focus on optimizing a VSE™ formulation for FUJIFILM Biosciences BalanCD HEK293 media to support academic and commercial AAV producers globally.
AAV vectors are a cornerstone of in vivo gene delivery for gene therapies, but they remain difficult and expensive to manufacture at scale. As pipelines expand to more indications and broader patient populations, significantly greater amounts of high-quality AAV are required, while the need for commercially viable therapies places pressure on cost-of-goods. Current manufacturing methods and underlying economics are often not sufficient to meet this demand. By pairing high-performance FUJIFILM Biosciences BalanCD media with Virica’s VSE enhancers, the collaboration aims to deliver significant AAV productivity gains and more robust, scalable processes.
To support FUJIFILM Biosciences’ product strategy, Virica will optimize VSE formulations and process parameters for AAV production in FUJIFILM Biosciences BalanCD HEK293 media with suspension HEK293 cells. This work will leverage Virica’s High-Throughput Virology (HTV™) platform, Design-of-Experiments (DoE) frameworks, and analytical testing. FUJIFILM Biosciences will contribute deep expertise in media and feed supplements and scale-up capabilities to the collaborative project. The project, supported by NRC IRAP, aims to generate VSE™ formulations tailored with the FUJIFILM Biosciences BalanCD HEK293 system, enabling an off-the-shelf enhancer–media combination that end users can adopt with minimal process changes.
“We see a strong fit between our VSE technology and FUJIFILM Biosciences BalanCD media portfolio,” said Dr. Jean-Simon Diallo, scientific co-founder and chief executive officer of Virica Biotech. “Following the recent launch of our CellVantage™ AAV off-the-shelf enhancer, our goal is to provide an optimized formulation to deliver further AAV productivity gains specifically in the FUJIFILM Biosciences BalanCD HEK293 system.”
“We remain committed to offering integrated solutions that combine high-performance media with enabling technologies,” said Yutaka Yamaguchi, chairman and chief executive officer atFUJIFILM Biosciences. “Optimizing Virica’s VSE-based enhancers with our FUJIFILM Biosciences BalanCD HEK293 system will help us deliver an easy-to-implement option for improving AAV yields and supporting efficient scale-up for our customers.”
To learn more about Virica’s support for the manufacture of viral vectors in cell and gene therapy and vaccines, please visit viricabiotech.com.
About Virica Biotech
Virica develops cell enhancers that improve the yield and quality of viral vectors used for cell & gene therapies and vaccines, allowing developers to deploy their products at scale economically. Virica’s Viral Sensitizer (VSE™) enhancers reduce production inefficiencies caused by cellular defenses in manufacturing cells. Purpose-formulated VSE combinations substantially increase manufacturing yields and reduce the cost of goods for a range of products. Beyond supplying VSEs as off-the-shelf reagents, Virica operates as a fast-turnaround service partner. Our proprietary High-Throughput Virology (HTV™) platform, Design-of-Experiments (DoE) process optimization, and analytical testing workflows enable developers to rapidly pinpoint the optimal transfection or transduction conditions, allowing programs to scale sooner and at a lower cost.
About FUJIFILM Biosciences
With a foundation in cell culture that dates back to 1970, FUJIFILM Biosciences is a global, full spectrum supplier to the life sciences market, providing products and services that assist customers in advancing healthcare initiatives. With an expanding portfolio of applications supported that include life science and discovery research, cell and gene therapy, as well as the large-scale production of biotherapeutics and vaccines, the Company is trusted by researchers and manufacturers worldwide. For over 50 years, FUJIFILM Biosciences’ Mission has been to empower all who bring medicines and treatments to life with unmatched quality and responsiveness in its products and custom solutions, providing customers with the vital resources needed to enrich human lives through innovative, accessible therapies. The Company’s facilities adhere to both ISO and FDA regulations, with manufacturing facilities that follow cGMP guidelines in the USA, Japan, and the Netherlands, and a media optimization center in China. All sites prioritize strategies that adhere to the FUJIFILM Sustainability Value Plan 2030 for sustainable growth. FUJIFILM Biosciences operates as a subsidiary of FUJIFILM Holdings America Corporation under FUJIFILM Holdings Corporation.
For more information, please visit: fujifilmbiosciences.fujifilm.com
FUJIFILM Holdings Corporation
FUJIFILM Holdings Corporation, headquartered in Tokyo, leverages its depth of knowledge and proprietary core technologies to deliver innovative products and services across the globe through the four key business segments of healthcare, electronics, business innovation, and imaging with over 70,000 employees. Guided and united by our Group Purpose of “giving our world more smiles,” we address social challenges and create a positive impact on society through our products, services, and business operations. Under its medium-term management plan, VISION2030, which ends in FY2030, we aspire to continue our evolution into a company that creates value and smiles for various stakeholders as a collection of global leading businesses and achieve a global revenue of 4 trillion yen (29 billion USD at an exchange rate of 140 JPY/USD). For more information, please visit: www.fujifilmholdings.com.
For further details about our commitment to sustainability and Fujifilm’s Sustainable Value Plan 2030, click here.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260407465758/en/
Contacts
For further information, please contact:
Virica Biotech
Dr. Jean-Simon Diallo
Email: communications@viricabiotech.com
Website: www.viricabiotech.com -
https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.viricabiote
ch.com&esheet=54482656&newsitemid=20260407465758&lan=en-US&anchor=www.viricabiot
ech.com&index=5&md5=3b7bed75986ab32e5bd88ed4f634ad81
FUJIFILM Biosciences
Lori Serles
Email: lori.serles@fujifilm.com
Phone: (949) 261-7800 x145
Lily Jeffery
Zyme Communications
Phone: +44 (0)7891 477 378
Email: lily.jeffery@zymecommunications.com
To opt-out from receiving press releases from Zyme Communications please e-mail
info@zymecommunications.com. To view our privacy policy, please click here -
https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.zymecommun
ications.com%2Fprivacy-policy%2F&esheet=54482656&newsitemid=20260407465758&lan=e
n-US&anchor=click+here&index=6&md5=6cbb938ddd549587a255d76e49e4a0cf.
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
OCP Announces Date of Third Quarter and Nine-Month 2026 Earnings19.11.2026 17:30:00 CET | Press Release
OCP S.A. (“OCP” or the “Company”), a global leader in the fertilizer industry, will release its third quarter and nine-month 2026 results on Monday, November 30, 2026. The results will be available to holders of the Company’s bonds, qualified institutional buyers, securities analysts and market makers on the OCP Intralinks portal from 7:00 a.m. EDT, 12:00 p.m. Morocco and London time (GMT). OCP senior management will host a conference call to discuss third quarter and nine-month 2026 results at 8:00 a.m. EDT, 1:00 p.m. Morocco and London time (GMT) on Monday, November 30, 2026, for holders of the Company’s bonds, qualified institutional buyers, securities analysts and market makers. Eligible parties that have not already registered for access to the Intralinks portal may do so by contacting the Investor Relations Department by emailing g.laraki@ocpgroup.ma. About OCP OCP is a global leader in the fertilizer industry, backed by almost a century’s production history. OCP has exclusive ac
ISACA Launches Updated COBIT 7 With Enhanced Assessment Model and Modern Digital Platform19.11.2026 16:24:00 CET | Press Release
When AI can spark fears about humanity’s future and aging technology can bring air travel to a standstill, the cost of weak governance is impossible to ignore. To help enterprises strengthen the governance of their information and technology, ISACA has launched COBIT 7, an updated version of its globally recognized framework for information and technology (I&T) governance. Built for a rapidly changing digital world, the new COBIT 7 framework combines trusted guidance, an intuitive digital platform, customizable resources, and practical tools to help practitioners turn technology into measurable value, align decisions with strategy and confidently navigate emerging risks, including AI. COBIT 7 reinforces the framework’s longstanding role in helping businesses align their I&T operations with broader strategic goals, manage technology risks, and ensure regulatory compliance. “Over the last 30 years, COBIT has been a trusted framework for countless organizations, providing a holistic, stru
North Star Carbon Removal Project Selected by Government of Canada for Landmark Carbon Removal Procurement Program19.11.2026 16:04:00 CET | Press Release
North Star, a planned large-scale carbon dioxide removal (CDR) project being developed by Meadow Lake Tribal Council (MLTC) and Svante Technologies Inc. (Svante), has been selected by the Government of Canada as a qualified supplier under the federal Request for Standing Offer (RFSO) for the Acquisition and Retirement of Credits from Carbon Dioxide Removal Projects. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261118228180/en/ The proposed North Star bioenergy with carbon capture and storage project is being developed by the Meadow Lake Tribal Council (MLTC) and Svante. The project will generate durable carbon dioxide removal credits by capturing biogenic CO2 from the MLTC Bioenergy Center in Meadow Lake, SK, Canada, and storing it deep underground in a geological storage site. North Star was one of only three bioenergy with carbon capture and storage (BECCS) projects selected through the competitive process, following a r
Xsolla Gives Games a New Home for Their Players on Desktop and the Web, With Rewards to Help Bring Players Back19.11.2026 15:32:00 CET | Press Release
Xsolla (USA), Inc., a global commerce company, is giving game developers two new capabilities designed to reach players and encourage repeat engagement. Xsolla Player and Xsolla Pages are now available, letting developers integrate quests, rewards, and partner-funded offers into the player flow. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261119175727/en/ Graphic: Xsolla Xsolla Player is a desktop app that players install once and access with their Xsolla ID, bringing their game library and inventory together without separate sign-ups for each game. Xsolla Pages creates search-optimized storefronts on the web for every title in a developer’s catalog, with direct checkout. PC studios work hard to win a player's first click, then work just as hard for every session after. Bringing players back is a challenge and has traditionally required paying to reach them again. Meanwhile, direct web sales have become a major revenue ch
From London 1851 to Riyadh 2030: The United Kingdom Continues Its World Expo Legacy with the Signing of Its Participation Contract for Expo 2030 Riyadh19.11.2026 15:10:00 CET | Press Release
The United Kingdom has signed its Participation Contract for Expo 2030 Riyadh, confirming its place at one of the world’s largest global gatherings. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261119617914/en/ The Participation Contract was signed by H.E Adel Al-Jubeir, Minister of State for Foreign Affairs, Climate Envoy, and Commissioner General of Expo 2030 Riyadh; and Lord Sarwar, UK Minister for Trade; and Talal Al-Marri, CEO of Expo 2030 Riyadh. The Agreement constitutes a significant milestone in the United Kingdom’s journey towards Expo 2030 Riyadh, establishing the framework for the execution of its pavilion, programming and visitor experience. This latest agreement adds to a growing number of Participation Contract signings, reflecting increasing momentum behind Expo 2030 Riyadh and the value countries are placing on being part of it. The Participation Contract was signed by H.E Adel Al-Jubeir, Minister of State
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom